科研之友ScholarMate
免费注册
首页 论文 论文详情
赞 收藏 引用

A randomized, double-blind, phase 2 study of ruxolitinib (RUX) or placebo (PBO) in combination with capecitabine (CAPE) in patients (pts) with advanced HER2-negative breast cancer (ABC) and elevated C-reactive protein (CRP), a marker of systemic inflammation

作者：O'Shaughnessy J; DeMichele A; Ma C; Richards P; Yardley D A; Wright G; Kalinsky K; Steis R; Di Ab S; Kennealey G; Geschwindt R; Jiang W; Rugo H
来源：San Antonio Breast Cancer Symposium, 2016-12-06 To 2016-12-10.
DOI：10.1158/1538-7445.SABCS16-P4-22-04
  • 出版日期2017-2

全文

全文

访问全文
收藏 分享 被引(1) 浏览
更新时间：2021-01-17 13:48